Bailey Pemberton
4 min read
Bio-Rad Laboratories has climbed back into focus after a mixed share price record, and the key issue now is whether the current US$372.18 level can be explained by the cash flows the business is expected to generate. With the Discounted Cash Flow (DCF) estimate in hand, the question is how well that intrinsic value lines up with what the market is paying today.
-
Over the past 5 years the stock has fallen 48.7%, which puts a lot of weight on whether the future cash flow profile really supports the current valuation after such a long reset.
-
Recent reports that Bio-Rad is a leading player across areas like microarray scanners, qPCR instruments and genetic testing suggest future revenue and investment demands that can reshape both the timing and durability of its cash flows.
-
What if you looked at Bio-Rad Laboratories through its earnings instead? See what Bio-Rad Laboratories’s 44.7x P/E says about the price.
The stock’s next move may depend on whether the Discounted Cash Flow (DCF) view of Bio-Rad Laboratories’ intrinsic value lines up with that US$372.18 share price or points to a different story for its cash flows.
If you are weighing Bio-Rad Laboratories against other life sciences opportunities tied to genomics, biomarkers and molecular testing, it can help to line it up next to 34 healthcare AI stocks.
Has Bio-Rad Laboratories Run Too Far on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash Bio-Rad Laboratories can return to shareholders over time, not just its reported earnings. Latest twelve month free cash flow sits at about $325.8 million, with the projections assuming that this pool of cash generally grows over the coming decade rather than shrinking.
Those estimates climb toward roughly $390 million of free cash flow by 2030 and then layer on more moderate gains, which presents a picture of a business that continues to invest in qPCR, genetic testing and biomarker tools without needing rapid expansion to justify its cash profile. Because the DCF output sits meaningfully below the current $372.18 share price, the market is assigning a richer tag to Bio-Rad Laboratories than its modeled cash flows alone would support. The push into microarray scanners highlighted in recent reports may help explain why investors are still willing to pay that premium even as the cash flow outlook appears more measured than the headline growth stories around genomics and precision medicine. Find out what Bio-Rad Laboratories could be worth using our Discounted Cash Flow (DCF) estimate.
